Akoya Biosciences Management
Management criteria checks 2/4
Akoya Biosciences' CEO is Brian McKelligon, appointed in Jul 2017, has a tenure of 6.75 years. total yearly compensation is $3.05M, comprised of 17% salary and 83% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $148.19K. The average tenure of the management team and the board of directors is 2.8 years and 3.7 years respectively.
Key information
Brian McKelligon
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 17.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?
Feb 28
Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump
Nov 25Akoya Biosciences Seeks Growth Despite Higher Operating Losses
May 30Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 11Akoya Biosciences and AstraZeneca ink collaboration agreement
Jun 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$71m |
| Jun 30 2023 | n/a | n/a | -US$76m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$3m | US$518k | -US$71m |
| Sep 30 2022 | n/a | n/a | -US$69m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$51m |
| Dec 31 2021 | US$2m | US$393k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | US$516k | US$350k | -US$22m |
| Dec 31 2019 | US$484k | US$333k | -US$18m |
Compensation vs Market: Brian's total compensation ($USD3.05M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.
CEO
Brian McKelligon (54 yo)
6.8yrs
Tenure
US$3,049,639
Compensation
Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$3.05m | 0.076% $ 148.2k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 1.1yrs | no data | 0.093% $ 182.0k | |
| Chief Operating Officer | 3.1yrs | US$3.33m | 0.062% $ 120.4k | |
| Senior Director of Business Development & Investor Relations Strategy | no data | no data | no data | |
| General Counsel | 1.2yrs | no data | 0.012% $ 24.3k | |
| Chief Business Officer | 3.7yrs | US$365.22k | 0.29% $ 576.3k | |
| Senior Vice President | 2.5yrs | no data | no data | |
| Secretary | no data | no data | no data |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Management: AKYA's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 6.8yrs | US$3.05m | 0.076% $ 148.2k | |
| Chairman of the Board | 8.4yrs | US$251.25k | 0.75% $ 1.5m | |
| Independent Director | 2.6yrs | US$230.62k | 0.041% $ 79.6k | |
| Independent Director | 4.6yrs | US$222.50k | no data | |
| Director | 8.4yrs | US$213.75k | 0.48% $ 933.7k | |
| Independent Director | 6.8yrs | US$231.25k | 2% $ 3.9m | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.8yrs | US$246.87k | 0.058% $ 113.4k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Chair of the Scientific Advisory Board | less than a year | US$218.75k | 1.26% $ 2.5m |
3.7yrs
Average Tenure
65yo
Average Age
Experienced Board: AKYA's board of directors are considered experienced (3.7 years average tenure).